Hey, we’ve posted new content about stem cells and cord blood that I’m excited to share with you. Let me know what you think.
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD. The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study.
In a July 2013 USA Today article, Rem Rieder discusses how Twitter “can function as a conveyor belt for first-rate journalism, bringing to your attention terrific material that you might otherwise never encounter”. He then goes on to point out that Twitter is a news pipeline for more than 200 million active users, often ‘breaking’ news before it’s actually news. In this article, you’ll learn the top 15 accounts to follow on Twitter to have breaking stem cell news delivered to your Twitter feed.
The discovery that we can induce plasticity in formerly fully differentiated cells is one of the greatest inventions of the last decades. In this article, Kevin Bielec, a Scientist at RheinCell Therapeutics GmbH, explores a several aspects that should be considered as future directions for iPSC-related research and development. RheinCell is a Düsseldorf-based company that specializes in research-grade production and characterization of human induced pluripotent stem cells (iPSC).